BioNeutra Global Corporation (BGACF) fair value: what the stock is really worth
As of Sep 18, 2026: fair value of BioNeutra Global Corporation $0.01, price $0.01, upside -0.5%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch BioNeutra Global Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
58‑month range $0.0035 – $0.9600 · fair‑value band $0.0054 – $0.0059 · the $0.0056 price screens above the $0.0056 fair value. Dashed = 300-day average. As of Sep 13, 2026.
BioNeutra Global Corporation engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products with a focus on oligosaccharides. The company offers isomalt oligosaccharide ingredients under the VitaFiber brand for human digestive health.
Show more
BioNeutra Global Corporation engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products with a focus on oligosaccharides. The company offers isomalt oligosaccharide ingredients under the VitaFiber brand for human digestive health. It operates in Canada, the United States, Australia, New Zealand, European Union, and the Asia Pacific. The company is headquartered in Vancouver, Canada.
Stock analysis
BioNeutra Global Corporation (BGACF) currently trades at $0.0056, while our model-based Fair Value estimate is $0.0056, implying the stock looks roughly 0.5% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 6 models at a data quality of 88/100, which puts the evidence level at low.
Scenario range: $0.0054 (bear) to $0.0059 (bull), the price of $0.0056 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
BioNeutra Global Corporation reported revenue of C$11.4M in FY2023 versus C$37.7M in FY2019, a compound −25.9%/yr. Reported net income was −C$2.1M in FY2023.
Key figures
Market cap $260K · P/S ratio 0.02 · EPS (TTM) $−0.0100 · Net margin −18.5% · Return on equity −255% · Return on assets (EBIT) −14.8% · Operating margin −9.2% · Revenue (TTM) $10.9M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades near its 52-week high, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −9% fair-value upside, at −1%, BGACF screens cheaper than that median.
Fair Value models
Bear $0.0054Fair Value $0.0056Bull $0.0059
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.10/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−15.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.3%
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
’12
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
8.9% (2018) → −12.6% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2023 is a loss year, no rate is defined from a loss
Compare BioNeutra Global Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 647 stocks
Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside+5% · Above median
Profitability
Return on assets−3% · Bottom 25%
Net margin (TTM)−6% · Bottom 25%
Operating margin (TTM)−9% · Bottom 25%
Growth and dividend
Revenue growth20% · Top 25%
Valuation Multiplesvs Packaged Foods median · lower = cheaper
P/S (TTM)0.02× · Cheapest 25%
P/FCF0.4× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)33· sector 26
FUTURE (revenue growth)100· sector 20
PAST (return on equity)0· sector 27
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 58
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BioNeutra Global Corporation Fair Value". https://www.fairvalue-calculator.com/stock/BGACF
Frequently asked questions
Is BioNeutra Global Corporation (BGACF) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.0056 versus a price of $0.0056, about −1% upside (fairly valued).
What is the fair value of BGACF?
Our model-based fair value for BioNeutra Global Corporation is $0.0056 (as of Sep 13, 2026), built from audited fundamentals. The current price: $0.0056.
What is the quality score of BGACF?
BioNeutra Global Corporation has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioNeutra Global Corporation (BGACF)?
Our model-based price target is the fair value of $0.0056 (as of Sep 13, 2026) from 6 valuation models. Cautious scenario $0.0054, optimistic scenario $0.0059. It is a calculation from audited fundamentals, not an analyst target.
What is the BioNeutra Global Corporation stock forecast for 2026?
Our models put fair value at $0.0056, about −1% upside versus a price of $0.0056 (fairly valued). Cautious scenario $0.0054, optimistic scenario $0.0059. The calculation is refreshed regularly with new filings.
What is the revenue of BioNeutra Global Corporation (BGACF)?
BioNeutra Global Corporation reported trailing-twelve-month revenue of about $10.9M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of BioNeutra Global Corporation (BGACF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioNeutra Global Corporation it is $0.0056 per share (as of Sep 13, 2026), against a price of $0.0056. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is BioNeutra Global Corporation stock overvalued or undervalued in 2026?
As of Sep 13, 2026, BGACF trades above its calculated fair value: price $0.0056, fair value $0.0056, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BGACF?
No. The price is what the market pays today ($0.0056); the fair value is what the company's own numbers justify ($0.0056). For BioNeutra Global Corporation the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioNeutra Global Corporation worth?
The market values BioNeutra Global Corporation at about $260K (market capitalisation, as of Sep 13, 2026). Per share that is $0.0056; our models calculate a fair value of $0.0056 per share.
What do the bullish and bearish scenarios say about BGACF?
Our models span a range for BioNeutra Global Corporation: cautious scenario $0.0054, base $0.0056, optimistic $0.0059 per share (as of Sep 13, 2026, price $0.0056). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BioNeutra Global Corporation (BGACF)?
Balance-sheet figures for BioNeutra Global Corporation (as of Sep 13, 2026): return on equity −255.4%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is BGACF from its 52-week high?
BioNeutra Global Corporation trades at $0.0056, about 0% below its 52-week high of $0.0056 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0056 is for.
Which stocks are comparable to BioNeutra Global Corporation?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, The Kraft Heinz Company, Foshan Haitian Flavouring and Food Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioNeutra Global Corporation stock attractive at the current price?
The data as of Sep 13, 2026: price $0.0056, calculated fair value $0.0056 (−1%), Quality Score 52/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BGACF calculated?
We run BioNeutra Global Corporation through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0056, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.2 % above its aggregate fair value. BioNeutra Global Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioNeutra Global Corporation (BGACF)?
The closing price on Sep 18, 2026 was $0.0056. Our model-based fair value is $0.0056, about −1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioNeutra Global Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0054 to $0.0059), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of BioNeutra Global Corporation
How large is the market capitalisation of BioNeutra Global Corporation (BGACF)?
The market capitalisation of BioNeutra Global Corporation is $260K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioNeutra Global Corporation (BGACF)?
The price-to-sales ratio of BioNeutra Global Corporation is 0.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioNeutra Global Corporation (BGACF)?
Earnings per share at BioNeutra Global Corporation are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BioNeutra Global Corporation (BGACF)?
The net margin of BioNeutra Global Corporation is −18.5% (fiscal year 2023). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioNeutra Global Corporation (BGACF)?
The return on equity (ROE) of BioNeutra Global Corporation is −255% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioNeutra Global Corporation (BGACF)?
On an EBIT basis the return on assets of BioNeutra Global Corporation is −14.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioNeutra Global Corporation (BGACF)?
The operating margin of BioNeutra Global Corporation is −9.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioNeutra Global Corporation (BGACF)?
Revenue at BioNeutra Global Corporation is growing +20.3% versus a year earlier (3y avg −22.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BioNeutra Global Corporation (BGACF) generate?
The free cash flow of BioNeutra Global Corporation is $664K (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does BioNeutra Global Corporation (BGACF) carry?
The net debt of BioNeutra Global Corporation is $5.8M (fiscal year 2023, ≈ 8.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BioNeutra Global Corporation in the live analysis
One click puts BioNeutra Global Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 13, 2026